[Effect of shenmai injection on sIL-2R NK and LAK cells in patients with advanced carcinoma].
Serum interleukin-2 receptor (sIL-2R) level activities of natural killer cell (NK) and lymphokine activated killer cell (LAK) cells were determined in 60 patients with advanced carcinoma (AC) before and after treatment with Shenmai injection (SMI), 40 healthy persons were taken as non-carcinoma control (NC). The results showed that: Serum sIL-2R level in AC were much higher than those in NC (P < 0.05) and activities of NK and LAK cells in AC were much lower than those in NC (P < 0.05) before treatment. There was no significant difference among gastric cancer, colonic carcinoma and lung cancer (P < 0.05). After treatment with SMI we also found that the level of sIL-2R in all patients were obviously lower (P < 0.05) while the activity of NK and LAK cells were significantly higher than that prior treatment (P < 0.05). Linear correlation was not found between sIL-2R and NK, LAK cells. These data suggested that the immune function was compromised in AC. The mechanism of the inhibitory effect of SMI on carcinoma might be related to the activity of biological response modifier.
Feng
P F
PF
Zhejiang Provincial Hospital of TCM, Hangzhou.
Liu
L M
LM
Shen
Y Y
YY
D000328:Adult; D000368:Aged; D003110:Colonic Neoplasms / Q000276:immunology; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D007694:Killer Cells, Natural / Q000276:immunology*; D008175:Lung Neoplasms / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000276:immunology
D004365:Drugs, Chinese Herbal; D007155:Immunologic Factors; D015375:Receptors, Interleukin-2